Latest Lipigon News & Updates

See the latest news and media coverage for Lipigon. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Lipigon

Biotech company developing blood lipid disorder treatments

lipigon.se
Headquarters
Umeå, Sweden
Founded year
2010
Company type
Public company
Number of employees
2–15

Latest news about Lipigon

Company announcements

  • Lipigon

    Nasdaq delists Lipigon from First North Growth Market

    The share is traded until and including 18 May 2026. The decision is motivated by the company not meeting the requirement for ongoing operations after phase II results.

  • Lipigon

    Lipigon’s board withdraws delisting proposal

    Nasdaq Stockholm initiates separate delisting process after phase II results. Last trading day expected May 18, 2026.

  • Lipigon

    Lipigon's board proposes delisting from Nasdaq First North

    The proposal is motivated by costs and strategic flexibility. CEO Johan Liwing terminates his agreement. AGM is held on May 18, 2026.

  • Lipigon

    Lipigon publishes year-end report 2025

    Reports phase II results for Lipisense®, cost savings and financial overview with operating result -32 218 tkr. Strategic review ongoing.

Unlock all announcements with a

Media coverage

  • EurekAlert!

    NTU Singapore, SUSTech and pharmaceutical firm Lipigon develop inhaled therapy to reduce lung damage from severe infections

    Nanyang Technological University, Singapore (NTU Singapore) is working with China’s Southern University of Science and Technology (SUSTech) and Swedish biotechnology company Lipigon Pharmaceuticals AB to...

  • Life Science Sweden

    Umeå company in turmoil after miss in study

    A miscalculation in a clinical study has put Umeå-based Lipigon Pharmaceuticals under hard pressure. A strategic review of the company is ongoing, and the board does not rule out that...

  • Affärsvärlden

    Emissionsguiden initiates coverage of Lipigon's rights issue

    Lipigon Pharmaceuticals' board of directors has decided on a rights issue that needs to be voted through at an extraordinary general meeting on April 28. Lipigon Pharmaceuticals develops treatments against so...

  • Dagens industri

    Lipigon on study results: "A disappointment"

    The research company Lipigon's previously announced rights issue has, according to a final outcome, been fully subscribed, of which approximately 36 percent was subscribed by guarantors. The company is thereby provided with 37.4...

Unlock all articles with a

Never miss news about Lipigon

Track Lipigon and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.